By Bhanvi Satija LONDON (Reuters) -Swiss drugmaker Novartis is exploring options to add more medicines to its ...

The coming flu season is the clearest indication yet that biopharma’s long-standing assumptions about predictability, ...

Novartis' blockbuster heart treatment Entresto saw sales growth stall in the third quarter of the year, dragging the Swiss ...

By Ludwig Burger and Bhanvi Satija FRANKFURT (Reuters) -Swiss drugmaker Novartis met third-quarter profit forecasts on ...

When investors seek to inject growth momentum into their portfolios, tech stocks are often the first choice. Companies like ...

Members of the 2024 bioprocessing training cohort. Photo courtesy of UNCP PEMBROKE — UNC Pembroke will offer a free, two-week bioprocessing course to prepare individuals for entry-level roles in the ...

The FDA announced a nationwide recall of over 140,000 bottles of a prescription cholesterol medication due to “failed ...

With an increasing number of available drugs along with a focus on early treatment regimens and drug sequencing in Crohn's disease, data from prospective, well designed studies to guide on drug choice ...

ITM-11 significantly improved PFS and OS in GEP-NET patients compared to everolimus, with a favorable safety profile and higher overall response rates. Dosimetry data showed targeted tumor uptake with ...

Now, it’s worth noting Stock Advisor’s total average return is 1,033% — a market-crushing outperformance compared to 193 % ...

Building on data showing radio’s edge in OTC advertising, Katz finds AM/FM drives double-digit awareness gains for a ...

Baron Health Care Fund gained for the quarter and outperformed its benchmark, the Russell 3000 Health Care Index. Read more ...